HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by van der Spek, E. Articles by Lokhorst, H.M. Search for Related Content PubMed PubMed Citation Articles by van der Spek, E. Articles by Lokhorst, H.M.

High dose Simvastatin does not reverse resistance to Vincristine, Adriamycin, and Dexamethasone (VAD) in Myeloma

¹ Department of Hematology, University Medical Center Utrecht, Utrecht, the Netherlands
² Department of Internal Medicine, Jeroen Bosch Hospital, ‘s-Hertogenbosch, the Netherlands

Correspondence: Dr. Henk M. Lokhorst, MD, PhD, Department of Hematology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands Tel: +31 30 2507655, Fax: +31 30 2511893, E-mail: H.Lokhorst{at}umcutrecht.nl

In a prospective phase II study, we evaluated the combination of high dose simvastatin and VAD chemotherapy in patients with refractory or relapsed multiple myeloma. Although treatment was feasible with mild side effects, only 1 of 12 patients achieved a partial response. According to our predefined criteria this was insufficient to continue the study.